Safety of Medicinal Products in Ukraine: Assessment of the Pharmacovigilance System and its Performance

The system is responsible for monitoring and managing adverse drug reactions, as well as identifying and mitigating potential risks associated with the use of medicinal products. In Ukraine, the pharmacovigilance system is governed by a framework of laws, regulations, and policies that aim to ensure the safe use of medicinal products. The pharmacovigilance system in Ukraine is comprised of several key components, including signal generation and data management, risk assessment and evaluation, and risk management and communication. The system relies on a network of stakeholders, including healthcare professionals, regulatory authorities, and pharmaceutical manufacturers, to collect and analyze data on adverse drug reactions and other safety issues. The assessment of the pharmacovigilance system in Ukraine found that the system is not functioning optimally. The system lacks a clear and comprehensive framework for signal generation and data management, which hinders the ability to identify and respond to potential safety issues. Additionally, the system lacks a robust risk assessment and evaluation process, which makes it difficult to determine the potential risks associated with the use of medicinal products. The assessment also found that the pharmacovigilance system in Ukraine is not well-coordinated, with multiple stakeholders operating in isolation and lacking a clear understanding of their roles and responsibilities. This lack of coordination hinders the ability to share information and coordinate responses to safety issues. The assessment identified several key findings and recommendations for improving the pharmacovigilance system in Ukraine. These include the need to establish a clear and comprehensive framework for signal generation and data management, as well as a robust risk assessment and evaluation process. Additionally, the assessment recommended the establishment of a national pharmacovigilance center to coordinate the activities of stakeholders and ensure the effective functioning of the system. The assessment also highlighted the importance of pharmacovigilance in public health programs, particularly in the context of infectious diseases such as HIV/AIDS and tuberculosis. The assessment found that the pharmacovigilance system in Ukraine is not well-equipped to respond to the safety issues associated with these diseases, and recommended the establishment of a comprehensive pharmacovigilance system to address these issues. In terms of implementation, the assessment recommended the establishment of a national pharmacovigilance center to coordinate the activities of stakeholders and ensure the effective functioning of the system. The center would be responsible for developing and implementing policies and procedures for signal generation and data management, risk assessment and evaluation, and risk management and communication. The center would also be responsible for coordinating the activities of stakeholders and ensuring the effective functioning of the system. The assessment also recommended the establishment of a comprehensive pharmacovigilance system to address the safety issues associated with infectious diseases such as HIV/AIDS and tuberculosis. This system would include a network of healthcare professionals, regulatory authorities, and pharmaceutical manufacturers who would work together to collect and analyze data on adverse drug reactions and other safety issues. In conclusion, the pharmacovigilance system in Ukraine is a critical component of ensuring the safety of medicinal products. However, the system is not functioning optimally, and several key findings and recommendations have been identified to improve its functioning. The establishment of a national pharmacovigilance center and a comprehensive pharmacovigilance system are critical to addressing the safety issues associated with medicinal products in Ukraine.